Abreva and Breastfeeding
No studies have been done on Abreva and breastfeeding, and the manufacturer recommends that women talk to their healthcare providers about this. Most healthcare providers consider the drug safe to take when breastfeeding; however, the exact effects it may have on a nursing infant are unknown. By discussing Abreva and breastfeeding with your healthcare provider, you can make a decision that is best for you.
It is not known if Abreva® (docosanol) passes through breast milk. The manufacturer of the drug recommends that breastfeeding women talk to their healthcare providers before taking it.
Abreva has not been studied in breastfeeding women; therefore, it is not known if the drug passes through breast milk or if it poses any risk to nursing infants. Many healthcare providers consider Abreva to be safe for use in most breastfeeding women, since very little medication reaches the bloodstream (in order for a medication to pass through breast milk, it must first reach the bloodstream).
You should talk with your healthcare provider about Abreva and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Abreva and breastfeeding that is right for you.